ClinicalTrials.Veeva

Menu

Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection (MCC/CC)

Reckitt Benckiser logo

Reckitt Benckiser

Status and phase

Completed
Phase 2

Conditions

Acute Respiratory Infection

Treatments

Drug: Placebo
Drug: Mucinex

Study type

Interventional

Funder types

Industry

Identifiers

NCT01114581
2010-MUC-01

Details and patient eligibility

About

The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.

Enrollment

38 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Symptoms of cough, thickened mucus and chest congestion
  • Able to produce sputum
  • Non Smoker

Exclusion criteria

  • Pregnant
  • Smokers
  • Fever above 101°F
  • Any chronic illness

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

38 participants in 2 patient groups, including a placebo group

Guaifenesin
Active Comparator group
Description:
Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
Treatment:
Drug: Mucinex
Placebo
Placebo Comparator group
Description:
Given as 2 tablets
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems